Navigation Links
Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
Date:1/5/2009

ytes (a type of white blood cell and part of the body's immune system) to the arterial wall, causing the inflammation that is characteristic of atherosclerosis.

The RWTH Aachen University scientists characterized the structure of the PF4-RANTES interactions using NMR spectroscopy and then designed a series of peptides to disrupt those interactions. One such peptide, termed CKEY2, is comprised of sequences from the RANTES protein. CKEY2 was shown to be stable and formed the secondary structural motif found in RANTES when stabilized by disulfide bridged cysteines at both ends of the peptide. The scientists demonstrated that CKEY2 disrupts PF4-RANTES heteromer formation by binding preferentially to RANTES. In vitro assays demonstrated that CKEY2 inhibited the recruitment of monocytes to endothelial cells. Finally, the scientists demonstrated that mice that are genetically predisposed to develop atherosclerosis when fed a high fat diet did not develop chronic arterial inflammation when injected with the mouse version of the CKEY2 peptide.

"With the efficacy of the PF4-RANTES inhibitor established in preclinical studies for atherosclerosis, we are expanding our work into pre-clinical studies in other inflammatory disease models," said Josh Schultz, Ph.D., Carolus Therapeutics' vice president of research. "Our ongoing collaboration with RWTH Aachen University involves the further exploration of chemokine interactions involved in inflammatory signaling."

In addition to targeting PF4-RANTES heterodimers, Carolus Therapeutics has a second drug discovery program targeting the pro-inflammatory cytokine MIF (Macrophage Migration Inhibitory Factor), which has emerged as a critical mediator of innate, cell-mediated immunity, immunoregulation and inflammation. Carolus Therapeutics' scientific founders previously identified two CXC chemokine receptors as novel functional receptors for MIF. Identification of structural moti
'/>"/>

SOURCE Carolus Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... to Identify Host Correlates of Protection Against Tuberculosis , ... OTTAWA, ... of products for biological sample collection, stabilization and preparation, today ... South African Tuberculosis Vaccine Initiative (SATVI), has chosen Oragene-DNA for ...
... 28 Dendreon Corporation (Nasdaq: DNDN ) announced ... IMPACT study in the New England Journal of Medicine ... in overall survival compared to control in men with asymptomatic ... manuscript is published in the July 29, 2010 ...
... 28 Burrill & Company, a San Francisco -based global ... Banking and Media, is pleased to announce that Shawn Cross ... , , , ... the Merchant Banking Group,s strategic growth plan, which includes a broad and ...
Cached Biology Technology:DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 2DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 3New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 2New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 3New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 4New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 5New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study 6Shawn Cross Appointed CEO of Burrill Merchant Banking Group 2Shawn Cross Appointed CEO of Burrill Merchant Banking Group 3
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... 16, 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... Chemical Sensor Market 2015-2019" report to their offering. ... One major trend upcoming in this market is the ... sensors help in recording of patient data for quick ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... A structural molecule and the cellular pump that regulates its ... ways of treating the lung infection, which is a leading ... University of Pittsburgh and the University of Iowa. Their findings ... Despite decades of research, there has been little new information ...
... key protein that regulates the biological clocks of mammals ... altering the levels of this protein can improve the ... this week,s advanced online publication of the journal ... for scientists to develop treatments for obesity and type ...
... Two researchers at Marshall University have been awarded ... the effects of omega-3 fatty acids on breast cancer ... Cancer Research Program has awarded Dr. Elaine Hardman, associate ... the Joan C. Edwards School of Medicine, and Dr. ...
Cached Biology News:Pitt/Iowa team finds cellular structural molecule can be toxic: Makes pneumonia worse 2Biologists discover biochemical link between biological clock and diabetes 2Biologists discover biochemical link between biological clock and diabetes 3Biologists discover biochemical link between biological clock and diabetes 4Marshall University researchers awarded more than $1 million for breast cancer studies 2Marshall University researchers awarded more than $1 million for breast cancer studies 3
... Workgroup solution is a highly scalable ... expression data in a workgroup or ... in over 40 leading pharmaceutical, biotechnology, ... GeneSpring Workgroup streamlines genomics research at ...
... for proteomic scale kinase profiling, quantitative ... drug discovery research built on the ... synthesis platform. These microarrays are available ... Kinase Substrate - Peptide Microarray Service. ...
... PEP-165 is an 18 amino acid synthetic peptide whose sequences ... peptide is (amino to carboxy terminus): S(21) - S - M ... D - E - A - I - D - K ... C(39). This peptide may be used for neutralization and ...
... containing peptidomimetics built on the flexible ... platform. These microarrays are available as ... Microarray Service. Custom Probe ... customer specified. Thousands of customer specified ...
Biology Products: